Table 1.
Variable | N | (%) | |
---|---|---|---|
Age (mean = 62; range=26-84) | <=50 | 41 | (16%) |
51~60 | 73 | (29%) | |
61~70 | 86 | (34%) | |
>70 | 55 | (22%) | |
Gender | Female | 118 | (46%) |
Male | 137 | (54%) | |
Ethnicity | Caucasian | 209 | (82%) |
Hispanic | 16 | (6%) | |
African American | 16 | (6%) | |
Asian | 14 | (5%) | |
Smoker | Current | 23 | (9%) |
Former | 177 | (69%) | |
Never | 55 | (22%) | |
Histology | Adenocacinoma | 160 | (63%) |
Squamous | 46 | (18%) | |
Others | 49 | (19%) | |
Prior erlotinib therapy | No | 139 | (55%) |
Yes | 116 | (46%) | |
ECOG performance status | 0 | 22 | (9%) |
1 | 197 | (77%) | |
2 | 36 | (14%) | |
Prior cytotoxic chemo therapy (median = 2; range=1-6) | 1 | 95 | (37%) |
2 | 84 | (33%) | |
3 | 40 | (16%) | |
4 | 24 | (9%) | |
5 | 9 | (4%) | |
6 | 3 | (1%) |